23 October 2025
Latham & Watkins Advises on Viridian Therapeutics’ up to US$300 Million Credit Upsizing With Hercules Capital and Related US$300 Million Royalty Financing With DRI Healthcare
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Emily Yu | Latham & Watkins LLP | Counsel | Not stated | Not stated |
| Hyunji Lee | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Scott Natsuhara | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Eric Rice | Latham & Watkins LLP | Partner | converts | Not stated |
Stated terms
- Stated value
- USD 300m (up to US$300 Million)
- What the figure measures
- Facility amount
- Client
- Hercules CapitalLenders
- Counterparties
- Viridian Therapeutics, Inc. (Borrower)
DRI Healthcare (Investor)